Tags

Type your tag names separated by a space and hit enter

Statins and new-onset diabetes: a retrospective longitudinal cohort study.

Abstract

BACKGROUND

Statins have been linked to new-onset diabetes (NOD); however, the effect of statins on the development of NOD in patients with hypertension and dyslipidemia has not been well studied.

OBJECTIVE

The goal of this study was to investigate the association between statins and NOD.

METHODS

This was a retrospective cohort study performed by using data from claim forms provided to the central regional branch of the Bureau of National Health Insurance in Taiwan from July 2006 to December 2009. Prescriptions for statins before the index date were retrieved from a prescription database. We estimated the hazards ratios (HRs) of NOD associated with statin use. Nondiabetic subjects served as the reference group.

RESULTS

A total of 1360 (8.5%) NOD cases were identified among 16,027 patients with hypertension and dyslipidemia during the study period. The risk of NOD after adjusting for sex and age was higher among users of pravastatin (HR, 1.34 [95% CI, 1.15-1.55]) and atorvastatin (HR, 1.29 [95% CI, 1.16-1.44]) than among nonusers. Patients who took fluvastatin (HR, 0.45 [95% CI, 0.34-0.60]), lovastatin (HR, 0.71 [95% CI, 0.61-0.84]), and rosuvastatin (HR, 0.54 [95% CI, 0.39-0.77]) were at lower risk of developing NOD than nonusers. Simvastatin was not associated with risk of NOD. Furthermore, the risk of NOD after adjusting for concomitant medication usage and mean dose of statins was neutral among users of atorvastatin. Pravastatin, fluvastatin, lovastatin, simvastatin, and rosuvastatin produced similar results as adjusting for sex and age.

CONCLUSIONS

These outpatients with hypertension and dyslipidemia who took fluvastatin, lovastatin, and rosuvastatin were at lower risk of NOD, whereas patients who took pravastatin were at greater risk. Simvastatin and atorvastatin seemed to have a neutral effect. Our study also demonstrated that atorvastatin has a dose-response effect on NOD risk. Because this was a descriptive study, temporality and subsequent causality of all statins and NOD could not be shown. Further study and independent confirmation of the causality between statin use and NOD in larger clinical trials are warranted.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Health Service Management, China Medical University, Taichung, Taiwan, Republic of China.

    , , ,

    Source

    Clinical therapeutics 34:9 2012 Sep pg 1977-83

    MeSH

    Adult
    Aged
    Aged, 80 and over
    Cohort Studies
    Diabetes Mellitus
    Dose-Response Relationship, Drug
    Dyslipidemias
    Female
    Humans
    Hydroxymethylglutaryl-CoA Reductase Inhibitors
    Hypertension
    Longitudinal Studies
    Male
    Middle Aged
    Proportional Hazards Models
    Retrospective Studies
    Risk
    Taiwan
    Young Adult

    Pub Type(s)

    Comparative Study
    Journal Article
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    22939164

    Citation

    Ma, Tsochiang, et al. "Statins and New-onset Diabetes: a Retrospective Longitudinal Cohort Study." Clinical Therapeutics, vol. 34, no. 9, 2012, pp. 1977-83.
    Ma T, Tien L, Fang CL, et al. Statins and new-onset diabetes: a retrospective longitudinal cohort study. Clin Ther. 2012;34(9):1977-83.
    Ma, T., Tien, L., Fang, C. L., Liou, Y. S., & Jong, G. P. (2012). Statins and new-onset diabetes: a retrospective longitudinal cohort study. Clinical Therapeutics, 34(9), pp. 1977-83. doi:10.1016/j.clinthera.2012.08.004.
    Ma T, et al. Statins and New-onset Diabetes: a Retrospective Longitudinal Cohort Study. Clin Ther. 2012;34(9):1977-83. PubMed PMID: 22939164.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Statins and new-onset diabetes: a retrospective longitudinal cohort study. AU - Ma,Tsochiang, AU - Tien,Liyun, AU - Fang,Chih-Ling, AU - Liou,Yi-Sheng, AU - Jong,Gwo-Ping, Y1 - 2012/08/30/ PY - 2012/03/20/received PY - 2012/07/30/revised PY - 2012/08/10/accepted PY - 2012/9/4/entrez PY - 2012/9/4/pubmed PY - 2013/2/6/medline SP - 1977 EP - 83 JF - Clinical therapeutics JO - Clin Ther VL - 34 IS - 9 N2 - BACKGROUND: Statins have been linked to new-onset diabetes (NOD); however, the effect of statins on the development of NOD in patients with hypertension and dyslipidemia has not been well studied. OBJECTIVE: The goal of this study was to investigate the association between statins and NOD. METHODS: This was a retrospective cohort study performed by using data from claim forms provided to the central regional branch of the Bureau of National Health Insurance in Taiwan from July 2006 to December 2009. Prescriptions for statins before the index date were retrieved from a prescription database. We estimated the hazards ratios (HRs) of NOD associated with statin use. Nondiabetic subjects served as the reference group. RESULTS: A total of 1360 (8.5%) NOD cases were identified among 16,027 patients with hypertension and dyslipidemia during the study period. The risk of NOD after adjusting for sex and age was higher among users of pravastatin (HR, 1.34 [95% CI, 1.15-1.55]) and atorvastatin (HR, 1.29 [95% CI, 1.16-1.44]) than among nonusers. Patients who took fluvastatin (HR, 0.45 [95% CI, 0.34-0.60]), lovastatin (HR, 0.71 [95% CI, 0.61-0.84]), and rosuvastatin (HR, 0.54 [95% CI, 0.39-0.77]) were at lower risk of developing NOD than nonusers. Simvastatin was not associated with risk of NOD. Furthermore, the risk of NOD after adjusting for concomitant medication usage and mean dose of statins was neutral among users of atorvastatin. Pravastatin, fluvastatin, lovastatin, simvastatin, and rosuvastatin produced similar results as adjusting for sex and age. CONCLUSIONS: These outpatients with hypertension and dyslipidemia who took fluvastatin, lovastatin, and rosuvastatin were at lower risk of NOD, whereas patients who took pravastatin were at greater risk. Simvastatin and atorvastatin seemed to have a neutral effect. Our study also demonstrated that atorvastatin has a dose-response effect on NOD risk. Because this was a descriptive study, temporality and subsequent causality of all statins and NOD could not be shown. Further study and independent confirmation of the causality between statin use and NOD in larger clinical trials are warranted. SN - 1879-114X UR - https://www.unboundmedicine.com/medline/citation/22939164/Statins_and_new_onset_diabetes:_a_retrospective_longitudinal_cohort_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0149-2918(12)00485-7 DB - PRIME DP - Unbound Medicine ER -